Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
977 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (401)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study | not yet recruiting | Phase 3 | 340 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 |
| Nov 24, 2025 |
| clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT07095608 | Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain | recruiting | N/A | 80 | New York UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05189730 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC(ETNT) | active not recruiting | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06592716 | Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples? | active not recruiting | — | 200 | Rigshospitalet, DenmarkOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06912074 | Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 134 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07086469 | Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)(SAVAL) | recruiting | Phase 2 | 61 | University of Maryland, BaltimoreOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05563766 | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | recruiting | Phase 2 | 78 | VA Office of Research and DevelopmentFED | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04574635 | Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer | active not recruiting | — | 18 | Mayo ClinicOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT03589339 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | active not recruiting | Phase 1 | 145 | NanobiotixINDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT04643379 | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | active not recruiting | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT06914999 | Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer | recruiting | Early Phase 1 | 20 | Emory UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT06597565 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | recruiting | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06699212 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases(ECLIPSE) | recruiting | Phase 3 | 412 | Rakuten Medical, Inc.INDUSTRY | 3 | Oct 15, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT03383094 | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | active not recruiting | Phase 2 | 126 | Loren Mell, MDOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05945875 | Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer | recruiting | Phase 1 | 40 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06664151 | A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision | recruiting | Early Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07203898 | A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 1 | 36 | Beijing Immupeutics Medicine Technology LimitedINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT05022654 | SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | active not recruiting | Phase 2 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05044897 | A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC | active not recruiting | Phase 2 | 11 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06006169 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 186 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07111455 | Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy | recruiting | — | 32 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07188103 | Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03396718 | De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas(DELPHI) | recruiting | N/A | 304 | Technische Universität DresdenOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05582122 | SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers(SURVEILLE-HPV) | recruiting | Phase 2 | 420 | UNICANCEROTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06469008 | A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06536257 | Personalised Immunotherapy Platform(PIP-PREDICT) | recruiting | — | 1,000 | Melanoma Institute AustraliaOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07180901 | Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer(PRONTO-HN) | recruiting | N/A | 85 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07010692 | Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment | recruiting | Phase 1 / Phase 2 | 100 | Bruce Robinson, MDOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06601309 | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC(ESCC) | recruiting | Phase 2 | 90 | Fujian Medical University Union HospitalOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07064330 | Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.(NGF-GRACE) | recruiting | — | 30 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06247956 | Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer | active not recruiting | Phase 2 | 153 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06686342 | PDO Based Drug Sensitive Test in R/M HNSCC | recruiting | — | 100 | Huashan HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07152535 | Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor(PKU-ESCC) | not yet recruiting | — | 255 | Peking University Cancer Hospital & InstituteOTHER | 0 | Sep 3, 2025 | clinicaltrials |
| NCT07152678 | Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma(BRIGHT-ESCC) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT03070366 | Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC(OMET) | active not recruiting | Phase 2 | 78 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03340896 | Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT(SALTORL) | active not recruiting | Phase 3 | 256 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Sep 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 24, 2025source: clinicaltrials